Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)3.17
  • Today's Change0.00 / 0.00%
  • Shares traded539.75k
  • 1 Year change23.83%
  • Beta0.7113
Data delayed at least 15 minutes, as of Jul 17 2019 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.

  • Revenue in USD (TTM)198.51m
  • Net income in USD-63.78m
  • Incorporated1986
  • Employees105.00
  • Location
    PDL BioPharma Inc932 Southwood BlvdINCLINE VILLAGE 89451United StatesUSA
  • Phone+1 (775) 832-8500
  • Fax+1 (775) 832-8501
  • Websitehttp://www.pdl.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Merus NV32.80m-24.74m361.67m98.00--3.71--11.03-1.08-1.081.434.170.1309--5.10334,730.70-9.87-41.80-11.37-49.24-----75.40-299.35----0.0112--43.50123.9762.53--79.62--
Collegium Pharmaceutical Inc291.18m-30.18m361.91m266.00--4.196.631.24-0.9114-0.91148.812.590.587920.643.851,094,662.00-6.09-46.02-10.94-66.8941.02---10.36-81.571.19-1.370.1175--884.73--47.74--159.74--
ProQR Therapeutics NV6.37m-45.32m362.46m119.00--3.98--56.88-1.24-1.240.17822.110.0789----53,549.58-56.45-39.05-63.70-42.22-----715.27-1,209.81----0.1131--285.35118.3815.45--17.89--
Eloxx Pharmaceuticals Inc0.00-50.51m365.97m29.00--9.60-----1.47-1.470.000.95790.00----0.00-132.84---163.02--------------0.2948-------99.78------
resTORbio, Inc.0.00-38.82m371.37m21.00--2.61-----1.37-1.370.003.980.00----0.00-27.50---28.66--------------0.00-------11.36------
Gritstone Oncology Inc2.53m-69.41m372.19m127.00--2.29--146.88-2.40-2.400.08754.56------22,424.78-------------2,739.07------0.00-------56.55------
NextCure Inc-100.00bn-100.00bn374.79m44.00--------------4.99----------------------------0.0437-------47.39------
Arcus Biosciences Inc8.85m-54.31m376.32m108.00--1.70--42.51-2.21-2.210.25514.980.0314--327.8981,972.22-19.26---20.47-------613.46------0.00--491.15--6.57------
BioCryst Pharmaceuticals, Inc.22.56m-106.53m381.68m100.00--16.95--16.92-0.999-0.9990.21280.20410.15165.994.22225,640.00-71.57-49.65-136.54-92.9191.9594.86-472.12-231.531.76-17.360.7861---18.003.57-53.92--64.92--
PDL BioPharma Inc198.51m-63.78m382.48m105.00--0.5643--1.93-0.4189-0.41891.425.620.19623.4310.341,890,524.00-6.3114.68-6.6217.2874.46---32.1639.3610.6724.510.154327.81-38.10-15.37-161.78---36.70--
Stealth BioTherapeutics Corp-100.00bn-100.00bn385.33m57.00--11.17----------0.9849----------------------------0.3298-------16.65------
Prothena Corporation PLC914.00k-127.77m389.48m59.00--1.25--426.12-3.20-3.200.02297.830.0017----15,491.53-23.97-28.05-25.16-29.92-----13,978.88-679.54----0.0152---96.537.15-1.31--25.67--
Beyondspring Inc0.00-48.51m391.12m52.00---------2.12-2.120.00-0.64010.00----0.00-322.77---1,266.41-------------100.02--------40.21------
Marker Therapeutics Inc205.99k-147.96m396.17m11.00--6.66--1,923.25-4.41-4.410.01081.310.0061----18,726.36-439.54-443.10-469.72-1,775.94-----71,827.72-109,881.50----0.00-------1,247.26------
AC Immune SA81.82m24.55m397.94m104.0018.371.6215.474.860.32060.32061.273.630.3732--82.38786,702.7011.20-10.6313.33-11.56----30.01-44.53--17.350.1696---64.48-3.59-92.92--49.48--
Data as of Jul 17 2019. Currency figures normalised to PDL BioPharma Inc's reporting currency: US Dollar USD

Institutional shareholders

58.90%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 31 Mar 201912.04m10.07%
BlackRock Fund Advisorsas of 31 Mar 201911.35m9.49%
The Vanguard Group, Inc.as of 31 Mar 201910.49m8.77%
Renaissance Technologies LLCas of 31 Mar 20199.63m8.05%
SSgA Funds Management, Inc.as of 31 Mar 20196.37m5.32%
Connor, Clark & Lunn Investment Management Ltd.as of 31 Mar 20194.99m4.17%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 20194.69m3.92%
Brandes Investment Partners LPas of 31 Mar 20194.35m3.63%
Charles Schwab Investment Management, Inc.as of 31 Mar 20193.47m2.90%
RBC Capital Markets LLC (Investment Management)as of 31 Mar 20193.09m2.59%
More ▼
Data from 31 Mar 2019 - 30 Jun 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.